Abstract Number: 1323 • 2013 ACR/ARHP Annual Meeting
Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has…Abstract Number: 957 • 2013 ACR/ARHP Annual Meeting
The Role Of S100A4 As a Biological Marker Of Immune Response In Early Rheumatoid Arthritis
Background/Purpose: We have previously demonstrated that S100A4 is up-regulated in established rheumatoid arthritis (RA) and that S100A4 regulates apoptosis and synthesis of matrix degrading enzymes…Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting
Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…Abstract Number: 478 • 2013 ACR/ARHP Annual Meeting
Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients
Background/Purpose: The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that transduce intracellular signaling for cytokines including interleukins and interferons, and…Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting
High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis. We studied…Abstract Number: 2416 • 2013 ACR/ARHP Annual Meeting
Discovery Of Novel Biomarkers In Rheumatoid Urine : Significance Of Urinary CD14
Background/Purpose: Current serum measures for assessing rheumatoid arthritis (RA) are invasive and are not highly sensitive to changes in disease activity. Thus, there is a…Abstract Number: 2395 • 2013 ACR/ARHP Annual Meeting
Plasma Short-Talin Is a New Rheumatoid Arthritis Monitoring Biomarker Independent Of The Inflammatory Markers
Methods: ). Sixteen (31.4 %) of these 51 patients were untreated, and 18 patients (35.3%) were treated with biologics DMARD at the time of collecting…Abstract Number: 2290 • 2013 ACR/ARHP Annual Meeting
Global Metabolite Profiling Of Synovial Fluids From Different Forms Of Inflammatory Arthritis For The Identification Of Putative Biomarker In Rheumatoid Arthritis
Background/Purpose: Metabolomics is the study of unique chemical fingerprints of specific cellular processes. Metabolite profiling is recently applied in identifying biomarkers in medical research including…Abstract Number: 2289 • 2013 ACR/ARHP Annual Meeting
Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the…Abstract Number: 2123 • 2012 ACR/ARHP Annual Meeting
Circulating Mir-223 Is Associated with Disease Activity and May Predict the Response to Therapy in Treatment naïve Patients with Early Rheumatoid Arthritis
Background/Purpose: Parameters/ predictors of treatment response in patients with early rheumatoid arthritis (ERA) are needed to optimize treatment management based on the expected disease course.…Abstract Number: 1764 • 2012 ACR/ARHP Annual Meeting
B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease
Background/Purpose: B cells are involved as central players in the pathogenesis of rheumatoid arthritis (RA). Our aim was to define whether a specific B cell…Abstract Number: 1321 • 2012 ACR/ARHP Annual Meeting
C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their clinical response to treatment. Despite considerable research, no…Abstract Number: 2664 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Background/Purpose : Anti-TNF therapy has become a standard therapeutic strategy for treatment of patients with rheumatoid arthritis (RA). A validated multi-biomarker disease activity algorithm (MBDA) blood…
ACR Meeting Abstracts